Compare HYLN & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYLN | EOLS |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.1M | 284.3M |
| IPO Year | 2019 | 2018 |
| Metric | HYLN | EOLS |
|---|---|---|
| Price | $1.93 | $4.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 857.1K | 802.2K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | $3,475,000.00 | ★ $297,176,000.00 |
| Revenue This Year | $197.93 | $13.27 |
| Revenue Next Year | $301.97 | $17.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 130.28 | 11.61 |
| 52 Week Low | $1.11 | $3.86 |
| 52 Week High | $2.56 | $12.28 |
| Indicator | HYLN | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 47.29 |
| Support Level | $1.91 | $4.10 |
| Resistance Level | $2.07 | $4.99 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 96.55 | 74.22 |
Hyliion Holdings Corp designs and develops power generators for stationary and mobile applications and provides R&D service. It provides solutions that enable clean, flexible, and affordable electricity production. The company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies. Its products and services include: KARNO Power Modules which is a modular, fully enclosed, fuel-agnostic and fully integrated power generating solution.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.